Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery

Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02432-17. doi: 10.1128/AAC.02432-17. Print 2018 Apr.

Abstract

An obese woman was treated with oral tedizolid 200 mg once daily for pseudoarthrosis 10 years after Roux-en-Y bypass surgery. Total plasma peak concentration was 2.12 mg/liter 3 h after intake, and area under the concentration-time curve from 0 to 24 h (AUC0-24) was 28.3 mg/liter · h. The AUC0-24/MIC ratio for unbound concentrations and for sensitive Staphylococcus and Streptococcus strains was ≥10.8, higher than the target ratio of 3. These results support the use of tedizolid without adjustment after bariatric surgery.

Keywords: bariatric surgery; obesity; pharmacokinetics; tedizolid.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology
  • Bariatric Surgery*
  • Female
  • Humans
  • Microbial Sensitivity Tests
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Oxazolidinones / pharmacokinetics*
  • Oxazolidinones / pharmacology
  • Staphylococcus / drug effects
  • Streptococcus / drug effects
  • Tetrazoles / pharmacokinetics*
  • Tetrazoles / pharmacology

Substances

  • Anti-Bacterial Agents
  • Oxazolidinones
  • Tetrazoles
  • tedizolid